This paper provides an overview of Primary Immune Regulatory Disorders (PIRDs) — a group of inborn errors of immunity characterized by immune dysregulation — and examines the emerging role of precision (targeted) therapies in their management.
The paper describes the landscape of PIRDs and highlights the transition toward precision therapy approaches tailored to specific molecular defects, though no specific trial outcomes or numerical results are reported in the available metadata.
The full text was not available for review; the summary is based on title, journal, and DOI metadata only, which limits extraction of specific findings, patient populations, and outcome data.
Clinicians managing patients with immune dysregulation should consider molecular diagnosis of PIRDs to guide targeted therapy selection. The precision therapy era offers the potential to match treatments to specific genetic defects rather than relying solely on broad immunosuppression.
Explore related topics
